On the CGI-I scale , the analysis revealed that MPH was more effective than ATX and GXR .
For any adverse events , RBX ( 89 % ) was the safest alternative .
Network meta- analysis offered a broader overview on the available treatments for ADHD , especially for safety issues , and contributes towards evidence gathering and clinical practice decisions .
The aim of this study is to gather evidence of head-to-head double-blind r and omized-controlled trials on the efficacy and safety of available treatments for attention deficit hyperactivity disorder ( ADHD ) in children and adolescents .
Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial
Attention deficit hyperactivity disorder ( ADHD ) is a common disorder of childhood that affects 3 % to 6 % of school-age children . Conventional stimulant medications are recognized by both specialists and parents as useful symptomatic treatment . Nevertheless , approximately 30 % of ADHD children treated with them do not respond adequately or can not tolerate the associated adverse effects . Such difficulties highlight the need for alternative safe and effective medications in the treatment of this disorder . Selegiline is a type B monoamine oxidase inhibitor ( MAOI ) that is metabolized to amphetamine and methamphetamine stimulant compounds that may be useful in the treatment of ADHD . The authors undertook this study to further evaluate , under double-blind and controlled conditions , the efficacy of selegiline for ADHD in children . A total of 28 children with ADHD as defined by DSM IV were r and omized to selegiline or methylpheni date  dosed on an age and weight-adjusted basis at selegiline 5 mg/day ( under 5 years ) and 10 mg/day ( over 5 years ) ( Group 1 ) and methylpheni date 1 mg/kg/day ( Group 2 ) for a 4-week double-blind clinical trial . The principal measure of the outcome was the Teacher and Parent ADHD Rating Scale . Patients were assessed by a child psychiatrist at baseline , 14 and 28 days after the medication started . No significant differences were observed between the two protocol s on the Parent and Teacher Rating Scale scores . Although the number of dropouts in the methylpheni date group was higher than in the selegiline group , there was no significant difference between the two protocol s in terms of the dropouts . Decreased appetite , difficulty falling asleep and headaches were observed more in the methylpheni date group . The results of this study must be considered preliminary , but they do suggest that selegiline may be beneficial in the treatment of ADHD . In addition , a tolerable side effect profile may be considered as one of the advantages of selegiline in the treatment of ADHD
On the CGI-I scale , the analysis revealed that MPH was more effective than ATX and GXR .
For any adverse events , RBX ( 89 % ) was the safest alternative .
Network meta- analysis offered a broader overview on the available treatments for ADHD , especially for safety issues , and contributes towards evidence gathering and clinical practice decisions .
The aim of this study is to gather evidence of head-to-head double-blind r and omized-controlled trials on the efficacy and safety of available treatments for attention deficit hyperactivity disorder ( ADHD ) in children and adolescents .